Chronic Dialysis Patients Are Depleted of Creatine: Review and Rationale for Intradialytic Creatine Supplementation.
Yvonne van der VeenAdrian PostDaan KremerChrista A KoopsErik MarsmanTheo Y Jerôme AppeldoornDaan J TouwRalf WesterhuisMargaretha Rebecca Heiner-FokkemaCasper F M FranssenTheo WallimannStephan J L BakkerPublished in: Nutrients (2021)
There is great need for the identification of new, potentially modifiable risk factors for the poor health-related quality of life (HRQoL) and of the excess risk of mortality in dialysis-dependent chronic kidney disease patients. Creatine is an essential contributor to cellular energy homeostasis, yet, on a daily basis, 1.6-1.7% of the total creatine pool is non-enzymatically degraded to creatinine and subsequently lost via urinary excretion, thereby necessitating a continuous supply of new creatine in order to remain in steady-state. Because of an insufficient ability to synthesize creatine, unopposed losses to the dialysis fluid, and insufficient intake due to dietary recommendations that are increasingly steered towards more plant-based diets, hemodialysis patients are prone to creatine deficiency, and may benefit from creatine supplementation. To avoid problems with compliance and fluid balance, and, furthermore, to prevent intradialytic losses of creatine to the dialysate, we aim to investigate the potential of intradialytic creatine supplementation in improving outcomes. Given the known physiological effects of creatine, intradialytic creatine supplementation may help to maintain creatine homeostasis among dialysis-dependent chronic kidney disease patients, and consequently improve muscle status, nutritional status, neurocognitive status, HRQoL. Additionally, we describe the rationale and design for a block-randomized, double-blind, placebo-controlled pilot study. The aim of the pilot study is to explore the creatine uptake in the circulation and tissues following different creatine supplementation dosages.
Keyphrases
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- double blind
- placebo controlled
- newly diagnosed
- prognostic factors
- randomized controlled trial
- metabolic syndrome
- gene expression
- cardiovascular disease
- risk factors
- weight loss
- cardiovascular events
- molecular dynamics
- open label
- patient reported outcomes
- coronary artery disease
- phase ii
- patient reported
- climate change
- phase iii